Vidprevtyn (COVID-19 coronavirus vaccine)

Main article: Vaccines against COVID-19 coronavirus

2021: The cost of the vaccine will be less than €10

On October 29, 2021, it became known that the COVID-19 vaccine, which the French drug manufacturer Sanofi developed together with the British partner GlaxoSmithKline, will cost less than €10, one of the company's executives said.

The vaccine, called Vidprevtyn, is based on a recombinant protein antigen developed by the Sanofi Pasteur vaccine unit, and also includes an immunosuppressive adjuvant developed by GSK, which is designed to increase the effectiveness of the drug itself.

Sanofi and Gsk created their coronavirus vaccine and named its price

Phase 3 of the trials, conducted in support of approval, uses a two-prick scheme: the first dose is directed against the original SARS-CoV-2 virus, and the second against the beta variant of B.1.351, first identified in South Africa. According to some studies, the beta variant may be most likely to evade the immune response stimulated by vaccines available on October 29, 2021, as well as some anti- SARS-CoV-2 antibody drugs, and is also considered more transmissible.

As of October 29, 2021, the EU approved four COVID-19 vaccines, two mRNA vaccines for Pfizer-BioNTech and Moderna, and two based on adenoviral vectors from AstraZeneca and Johnson & Johnson (J&J). Four are under consideration, including another recombinant protein-based adjuvant vaccine from Novavax, an mRNA-based vaccine from CureVax, the Russian adenovirus Sputnik V, and an inactivated virus-based vaccine developed by Chinese company Sinovac Life Sciences.

During a consistent examination, the European Medicines Agency (EMA) will analyze data on the drug in the future of its use in the European Union (EU). According to EMA, Vidprevtyn contains a laboratory-grown version of the spike-like protein found on the surface of the SARS-CoV-2, as well as an adjuvant, a substance that helps strengthen the immune response to the vaccine. This technology differs from the m-RNA vaccines Pfizer-BioNTech and Moderna already used in Europe, as well as vector AstraZeneca and J & J. Regarding the timing, vaccines may be approved by the EMA by the end of 2021 or early 2022.

Sanofi hopes to return after lagging behind competitors in the race for COVID-19 injections and expects to receive full results from mass trials of the planned vaccine by the end of 2021. Thomas Triomf, head of Sanofi Pasteur's vaccine division, said on a conference call with analysts that the company is looking to build towards practicality and versatility in the field of vaccines that can be used as an aid to drugs already on the market.^[1]

2020: GSK and Sanofi received $2.1 billion from US authorities to develop 100 million doses of coronavirus vaccines

At the end of July 2020, it became known that the US authorities paid $2.1 billion to Sanofi and GlaxoSmithKline for vaccines against COVID-19. These funds will go to research and production of a candidate vaccine, and the purchased volume should be enough to vaccinate 50 million people. More details here.

Notes